Abstract
Although advances in chemotherapy have improved the prognosis for osteosarcoma, some patients do not respond sufficiently to treatment. Heat shock protein 70 (Hsp70) is expressed at high levels in cancer cells and attenuates the therapeutic efficacy of anticancer agents, resulting in a poorer prognosis. This study investigated whether small interfering RNA (siRNA)-mediated inhibition of Hsp70 expression in an osteosarcoma cell line would enhance sensitivity to cisplatin. The expression of Hsp70 with cisplatin treatment was observed by using Western blotting and real-time reverse transcription polymerase chain reaction (RT-PCR). Changes in the IC50 of cisplatin when Hsp70 was inhibited by siRNA were evaluated. Cisplatin’s effectiveness in inducing apoptosis was assessed by assay of terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL), caspase-3 activity, and mitochondrial membrane potential. Up-regulation of Hsp70 expression was dependent on the concentration of cisplatin. Inhibition of Hsp70 expression significantly reduced the IC50 of cisplatin. When cisplatin was added to osteosarcoma cells with Hsp70 expression inhibited, a significant increase in apoptosis was demonstrated in TUNEL, caspase-3, and mitochondrial membrane potential assays. Inhibition of Hsp70 expression induced apoptosis in cultured osteosarcoma cells, indicating that Hsp70 inhibition enhanced sensitivity to cisplatin. Inhibition of Hsp70 expression may provide a new adjuvant therapy for osteosarcoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aghdassi A et al (2007) Heat shock protein 70 increases tumorigenicity and inhibits apoptosis in pancreatic adenocarcinoma. Cancer Res 67:616–625. doi:10.1158/0008-5472.can-06-1567
Anderson ME (2016) Update on survival in osteosarcoma. The Orthopedic clinics of North America 47:283–292. doi:10.1016/j.ocl.2015.08.022
Asling J, Morrison J, Mutsaers AJ (2016) Targeting HSP70 and GRP78 in canine osteosarcoma cells in combination with doxorubicin chemotherapy. Cell Stress Chaperones 21:1065–1076. doi:10.1007/s12192-016-0730-4
Barba AA et al (2017) Engineering approaches in siRNA delivery. Int J Pharm. doi:10.1016/j.ijpharm.2017.02.032
Behnsawy HM, Miyake H, Kusuda Y, Fujisawa M (2013) Small interfering RNA targeting heat shock protein 70 enhances chemosensitivity in human bladder cancer cells. Urol Oncol 31:843–848. doi:10.1016/j.urolonc.2011.07.007
Bruning A, Juckstock J (2015) Misfolded proteins: from little villains to little helpers in the fight against cancer. Front Oncol 5:47. doi:10.3389/fonc.2015.00047
Calderwood SK, Gong J (2016) Heat shock proteins promote cancer: it’s a protection racket. Trends Biochem Sci 41:311–323. doi:10.1016/j.tibs.2016.01.003
Ciocca DR, Calderwood SK (2005) Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10:86–103
Cummings BS, Schnellmann RG (2002) Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J Pharmacol Exp Ther 302:8–17
Damron TA, Ward WG, Stewart A (2007) Osteosarcoma, chondrosarcoma, and Ewing’s sarcoma: National Cancer Data Base Report. Clin Orthop Relat Res 459:40–47. doi:10.1097/BLO.0b013e318059b8c9
Dasari S, Tchounwou PB (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740:364–378. doi:10.1016/j.ejphar.2014.07.025
Ferlini C, Scambia G (2007) Assay for apoptosis using the mitochondrial probes, rhodamine123 and 10-N-nonyl acridine orange. Nat Protoc 2:3111–3114. doi:10.1038/nprot.2007.397
Ferrari S, Palmerini E (2007) Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 19:341–346. doi:10.1097/CCO.0b013e328122d73f
Ferrari S, Serra M (2015) An update on chemotherapy for osteosarcoma Expert Opin Pharmacother 16:2727–2736. doi:10.1517/14656566.2015.1102226
Fleuren ED et al (2014) Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models. International journal of cancer Journal international du cancer 135:2770–2782. doi:10.1002/ijc.28933
Gimenez Ortiz A, Montalar Salcedo J (2010) Heat shock proteins as targets in oncology. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 12:166–173. doi:10.1007/s12094-010-0486-8
Goloudina AR, Demidov ON, Garrido C (2012) Inhibition of HSP70: a challenging anti-cancer strategy. Cancer Lett 325:117–124. doi:10.1016/j.canlet.2012.06.003
Guttmann DM, Koumenis C (2011) The heat shock proteins as targets for radiosensitization and chemosensitization in cancer. Cancer biology & therapy 12:1023–1031. doi:10.4161/cbt.12.12.18374
Inoue H et al (2014) Sonoporation-mediated transduction of siRNA ameliorated experimental arthritis using 3 MHz pulsed ultrasound. Ultrasonics 54:874–881. doi:10.1016/j.ultras.2013.10.021
Jaattela M, Wissing D, Bauer PA, Li GC (1992) Major heat shock protein hsp70 protects tumor cells from tumor necrosis factor cytotoxicity. EMBO J 11:3507–3512
Jaattela M, Wissing D (1993) Heat-shock proteins protect cells from monocyte cytotoxicity: possible mechanism of self-protection. J Exp Med 177:231–236
Li GC, Li L, Liu RY, Rehman M, Lee WM (1992) Heat shock protein hsp70 protects cells from thermal stress even after deletion of its ATP-binding domain. Proc Natl Acad Sci U S A 89:2036–2040
Liu D, Yan L, Wang L, Tai W, Wang W, Yang C (2014a) Genistein enhances the effect of cisplatin on the inhibition of non-small cell lung cancer A549 cell growth in vitro and in vivo. Oncol Lett 8:2806–2810. doi:10.3892/ol.2014.2597
Liu Y et al (2014b) A novel androstenedione derivative induces ROS-mediated autophagy and attenuates drug resistance in osteosarcoma by inhibiting macrophage migration inhibitory factor (MIF). Cell Death Dis 5:e1361. doi:10.1038/cddis.2014.300
Moon A, Bacchini P, Bertoni F, Olvi LG, Santini-Araujo E, Kim YW, Park YK (2010) Expression of heat shock proteins in osteosarcomas. Pathology 42:421–425. doi:10.3109/00313025.2010.493866
Pocaly M et al (2007) Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia. Leukemia 21:93–101. doi:10.1038/sj.leu.2404463
Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33:9–23. doi:10.1016/j.ctrv.2006.09.006
Saleh A, Srinivasula SM, Balkir L, Robbins PD, Alnemri ES (2000) Negative regulation of the Apaf-1 apoptosome by Hsp70. Nat Cell Biol 2:476–483. doi:10.1038/35019510
Seki K, Yoshikawa H, Shiiki K, Hamada Y, Akamatsu N, Tasaka K (2000) Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma. Cancer Chemother Pharmacol 45:199–206. doi:10.1007/s002800050030
Takeda A, Tsuchiya H, Tajino T, Kikuchi S (2005) An experimental study on the therapeutic effect of consecutive low-dose cisplatin with caffeine in sarcoma-bearing mice. Anticancer Res 25:2777–2784
Terauchi R et al (2003) Hsp70 prevents nitric oxide-induced apoptosis in articular chondrocytes. Arthritis Rheum 48:1562–1568. doi:10.1002/art.11040
Uozaki H et al (2000) Expression of heat shock proteins in osteosarcoma and its relationship to prognosis. Pathol Res Pract 196:665–673. doi:10.1016/s0344-0338(00)80118-1
Yamamoto N, Tsuchiya H (2013) Chemotherapy for osteosarcoma—where does it come from? What is it? Where is it going? Expert Opin Pharmacother 14:2183–2193. doi:10.1517/14656566.2013.827171
Yang X, Wang J, Zhou Y, Wang Y, Wang S, Zhang W (2012) Hsp70 promotes chemoresistance by blocking Bax mitochondrial translocation in ovarian cancer cells. Cancer Lett 321:137–143. doi:10.1016/j.canlet.2012.01.030
Zhang Y, Huang L, Zhang J, Moskophidis D, Mivechi NF (2002) Targeted disruption of hsf1 leads to lack of thermotolerance and defines tissue-specific regulation for stress-inducible Hsp molecular chaperones. J Cell Biochem 86:376–393. doi:10.1002/jcb.10232
Zhang Z, Shao Z, Xiong L, Yang S (2015) Inhibition of autophagy enhances cisplatin-induced apoptosis in the MG63 human osteosarcoma cell line. Oncol Lett 10:2941–2946. doi:10.3892/ol.2015.3692
Zhao L, Jiang BO, Wang D, Liu W, Zhang H, Liu W, Qiu Z (2016) Triptolide reduces the viability of osteosarcoma cells by reducing MKP-1 and Hsp70 expression. Experimental and therapeutic medicine 11:2005–2010. doi:10.3892/etm.2016.3164
Acknowledgments
This work was supported by JSPS KAKENHI Grant Number 26462273 and 16H05452.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Mori, Y., Terauchi, R., Shirai, T. et al. Suppression of heat shock protein 70 by siRNA enhances the antitumor effects of cisplatin in cultured human osteosarcoma cells. Cell Stress and Chaperones 22, 699–706 (2017). https://doi.org/10.1007/s12192-017-0793-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12192-017-0793-x